{"id":10766,"date":"2018-07-19T16:54:09","date_gmt":"2018-07-19T20:54:09","guid":{"rendered":"https:\/\/research.ncsu.edu\/otcnv\/?p=10766"},"modified":"2023-11-20T19:48:07","modified_gmt":"2023-11-21T00:48:07","slug":"locus-biosciences-acquires-epibiome","status":"publish","type":"post","link":"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/","title":{"rendered":"Locus Biosciences acquires EpiBiome&#8217;s high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics"},"content":{"rendered":"\n\n\n\n\n<p>Locus Biosciences Inc., an emerging biotechnology company developing CRISPR-Cas3-engineered precision antibacterial products, announced today its acquisition of EpiBiome, Inc.&#8217;s high-throughput bacteriophage (&#8220;phage&#8221;) discovery platform. Pairing EpiBiome&#8217;s powerful phage isolation and characterization capability with Locus&#8217;s CRISPR-based synthetic biology platform and clinical development team creates a combined entity that is rapidly developing products to treat antibiotic-resistant bacterial infections and precisely edit the microbiome. Terms of the deal are undisclosed.<\/p>\n\n\n<div class=\"wp-block-ncst-buttons\"><div class=\"wp-block-ncst-button\"><a href=\"https:\/\/www.prnewswire.com\/news-releases\/locus-biosciences-acquires-epibiomes-high-throughput-discovery-platform-to-enhance-its-global-leadership-in-crispr-engineered-phage-therapeutics-300680648.html\" class=\"btn ncst-block__button-link\" data-ncst-lightbox=\"false\" data-ua-cat=\"Button Block\" data-ua-action=\"Button Click\" data-ua-label=\"https:\/\/www.prnewswire.com\/news-releases\/locus-biosciences-acquires-epibiomes-high-throughput-discovery-platform-to-enhance-its-global-leadership-in-crispr-engineered-phage-therapeutics-300680648.html\"><span class=\"text\">Read More<\/span><span class=\"arrow-indicator\"><svg \n\tclass=\"wolficon wolficon-arrow-right-bold\"\n\trole=\"img\"\n\taria-hidden=\"1\">\n\t\t<use xlink:href=\"#wolficon-arrow-right-bold\"><\/use>\n<\/svg>\n<\/span><\/a><\/div>\n\n<\/div>\n\n","protected":false,"raw":"<!-- wp:ncst\/dynamic-header {\"block\":\"ncst\/default-post-header\"} -->\n<!-- wp:ncst\/default-post-header {\"caption\":\"\",\"showAuthor\":false,\"showReadingTime\":false} \/-->\n<!-- \/wp:ncst\/dynamic-header -->\n\n<!-- wp:paragraph -->\n<p>Locus Biosciences Inc., an emerging biotechnology company developing CRISPR-Cas3-engineered precision antibacterial products, announced today its acquisition of EpiBiome, Inc.'s high-throughput bacteriophage (\"phage\") discovery platform. Pairing EpiBiome's powerful phage isolation and characterization capability with Locus's CRISPR-based synthetic biology platform and clinical development team creates a combined entity that is rapidly developing products to treat antibiotic-resistant bacterial infections and precisely edit the microbiome. Terms of the deal are undisclosed.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:ncst\/buttons -->\n<div class=\"wp-block-ncst-buttons\"><!-- wp:ncst\/button -->\n<div class=\"wp-block-ncst-button\"><a href=\"https:\/\/www.prnewswire.com\/news-releases\/locus-biosciences-acquires-epibiomes-high-throughput-discovery-platform-to-enhance-its-global-leadership-in-crispr-engineered-phage-therapeutics-300680648.html\" class=\"btn ncst-block__button-link\" data-ncst-lightbox=\"false\" data-ua-cat=\"Button Block\" data-ua-action=\"Button Click\" data-ua-label=\"https:\/\/www.prnewswire.com\/news-releases\/locus-biosciences-acquires-epibiomes-high-throughput-discovery-platform-to-enhance-its-global-leadership-in-crispr-engineered-phage-therapeutics-300680648.html\"><span class=\"text\">Read More<\/span><span class=\"arrow-indicator\"><!-- wp:ncst\/wolficon {\"slug\":\"arrow-right-bold\"} -->\n<svg class=\"wp-block-ncst-wolficon wolficon\" role=\"img\" aria-hidden=\"true\"><use xlink:href=\"#wolficon-arrow-right-bold\"\/><\/svg>\n<!-- \/wp:ncst\/wolficon --><\/span><\/a><\/div>\n<!-- \/wp:ncst\/button --><\/div>\n<!-- \/wp:ncst\/buttons -->"},"excerpt":{"rendered":"<p>Locus Biosciences Inc., an emerging biotechnology company developing CRISPR-Cas3-engineered precision antibacterial products, announced today its acquisition of EpiBiome, Inc.&#8217;s high-throughput bacteriophage (&#8220;phage&#8221;) discovery platform. Pairing EpiBiome&#8217;s powerful phage isolation and&hellip;<\/p>\n","protected":false},"author":239,"featured_media":15171,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"source":"","ncst_custom_author":"","ncst_show_custom_author":false,"ncst_dynamicHeaderBlockName":"ncst\/default-post-header","ncst_dynamicHeaderData":"{\"showAuthor\":false,\"showDate\":true,\"showFeaturedVideo\":false,\"caption\":\"\",\"showReadingTime\":false}","ncst_content_audit_freq":"","ncst_content_audit_date":"","ncst_content_audit_display":false,"ncst_backToTopFlag":"","footnotes":""},"categories":[2,3],"tags":[11,21,35,61,67,76,119],"_ncst_magazine_issue":[],"class_list":["post-10766","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-startup-news","tag-antibacterial","tag-bacteriophage","tag-biotech","tag-crispr","tag-dna","tag-epibiomes","tag-locus-biosciences"],"displayCategory":null,"acf":{"ncst_posts_meta_modified_date":null},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Locus Biosciences acquires EpiBiome&#039;s high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics - Office of Research Commercialization<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Locus Biosciences acquires EpiBiome&#039;s high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics - Office of Research Commercialization\" \/>\n<meta property=\"og:description\" content=\"Locus Biosciences Inc., an emerging biotechnology company developing CRISPR-Cas3-engineered precision antibacterial products, announced today its acquisition of EpiBiome, Inc.&#8217;s high-throughput bacteriophage (&#8220;phage&#8221;) discovery platform. Pairing EpiBiome&#8217;s powerful phage isolation and&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/\" \/>\n<meta property=\"og:site_name\" content=\"Office of Research Commercialization\" \/>\n<meta property=\"article:published_time\" content=\"2018-07-19T20:54:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-21T00:48:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1601\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sasha Campbell\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sasha Campbell\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/\"},\"author\":{\"name\":\"Sasha Campbell\",\"@id\":\"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8\"},\"headline\":\"Locus Biosciences acquires EpiBiome&#8217;s high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics\",\"datePublished\":\"2018-07-19T20:54:09+00:00\",\"dateModified\":\"2023-11-21T00:48:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/\"},\"wordCount\":90,\"image\":{\"@id\":\"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png\",\"keywords\":[\"antibacterial\",\"bacteriophage\",\"biotech\",\"CRISPR\",\"dna\",\"epibiomes\",\"Locus Biosciences\"],\"articleSection\":[\"News\",\"Startup News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/\",\"url\":\"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/\",\"name\":\"Locus Biosciences acquires EpiBiome's high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics - Office of Research Commercialization\",\"isPartOf\":{\"@id\":\"https:\/\/research.ncsu.edu\/commercialization\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png\",\"datePublished\":\"2018-07-19T20:54:09+00:00\",\"dateModified\":\"2023-11-21T00:48:07+00:00\",\"author\":{\"@id\":\"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8\"},\"breadcrumb\":{\"@id\":\"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/#primaryimage\",\"url\":\"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png\",\"contentUrl\":\"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png\",\"width\":1601,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/research.ncsu.edu\/commercialization\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Locus Biosciences acquires EpiBiome&#8217;s high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/research.ncsu.edu\/commercialization\/#website\",\"url\":\"https:\/\/research.ncsu.edu\/commercialization\/\",\"name\":\"Office of Research Commercialization\",\"description\":\"Just another Research and Innovation site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/research.ncsu.edu\/commercialization\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8\",\"name\":\"Sasha Campbell\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g\",\"caption\":\"Sasha Campbell\"},\"url\":\"https:\/\/research.ncsu.edu\/commercialization\/author\/sasha-campbell\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Locus Biosciences acquires EpiBiome's high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics - Office of Research Commercialization","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/","og_locale":"en_US","og_type":"article","og_title":"Locus Biosciences acquires EpiBiome's high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics - Office of Research Commercialization","og_description":"Locus Biosciences Inc., an emerging biotechnology company developing CRISPR-Cas3-engineered precision antibacterial products, announced today its acquisition of EpiBiome, Inc.&#8217;s high-throughput bacteriophage (&#8220;phage&#8221;) discovery platform. Pairing EpiBiome&#8217;s powerful phage isolation and&hellip;","og_url":"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/","og_site_name":"Office of Research Commercialization","article_published_time":"2018-07-19T20:54:09+00:00","article_modified_time":"2023-11-21T00:48:07+00:00","og_image":[{"width":1601,"height":900,"url":"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png","type":"image\/png"}],"author":"Sasha Campbell","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sasha Campbell"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/#article","isPartOf":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/"},"author":{"name":"Sasha Campbell","@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8"},"headline":"Locus Biosciences acquires EpiBiome&#8217;s high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics","datePublished":"2018-07-19T20:54:09+00:00","dateModified":"2023-11-21T00:48:07+00:00","mainEntityOfPage":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/"},"wordCount":90,"image":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/#primaryimage"},"thumbnailUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png","keywords":["antibacterial","bacteriophage","biotech","CRISPR","dna","epibiomes","Locus Biosciences"],"articleSection":["News","Startup News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/","url":"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/","name":"Locus Biosciences acquires EpiBiome's high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics - Office of Research Commercialization","isPartOf":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/#website"},"primaryImageOfPage":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/#primaryimage"},"image":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/#primaryimage"},"thumbnailUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png","datePublished":"2018-07-19T20:54:09+00:00","dateModified":"2023-11-21T00:48:07+00:00","author":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8"},"breadcrumb":{"@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/#primaryimage","url":"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png","contentUrl":"https:\/\/research.ncsu.edu\/commercialization\/files\/2019\/02\/ORC-news-photo-.png","width":1601,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/research.ncsu.edu\/commercialization\/2018\/07\/19\/locus-biosciences-acquires-epibiome\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/research.ncsu.edu\/commercialization\/"},{"@type":"ListItem","position":2,"name":"Locus Biosciences acquires EpiBiome&#8217;s high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/research.ncsu.edu\/commercialization\/#website","url":"https:\/\/research.ncsu.edu\/commercialization\/","name":"Office of Research Commercialization","description":"Just another Research and Innovation site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/research.ncsu.edu\/commercialization\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/2df2b886ab8c62292fb07ec4b03d51e8","name":"Sasha Campbell","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/research.ncsu.edu\/commercialization\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/edfb3837fd495d2c22bb5f130242f0fd2a18560716a726ebe999c70c8cc2bcb1?s=96&d=mm&r=g","caption":"Sasha Campbell"},"url":"https:\/\/research.ncsu.edu\/commercialization\/author\/sasha-campbell\/"}]}},"_links":{"self":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/10766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/users\/239"}],"replies":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/comments?post=10766"}],"version-history":[{"count":2,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/10766\/revisions"}],"predecessor-version":[{"id":15177,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/posts\/10766\/revisions\/15177"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/media\/15171"}],"wp:attachment":[{"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/media?parent=10766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/categories?post=10766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/tags?post=10766"},{"taxonomy":"_ncst_magazine_issue","embeddable":true,"href":"https:\/\/research.ncsu.edu\/commercialization\/wp-json\/wp\/v2\/_ncst_magazine_issue?post=10766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}